Related Experiment Videos
Human immunodeficiency virus type 1 protease inhibitors
1Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA.
Archives of Internal Medicine
|May 12, 1997
Summary
New human immunodeficiency virus type 1 (HIV-1) protease inhibitors offer greater antiviral activity than older treatments. These potent drugs suppress HIV-1 replication, addressing limitations of previous therapies.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Previous human immunodeficiency virus type 1 (HIV-1) treatment relied on nucleoside reverse transcriptase inhibitors.
- These earlier treatments demonstrated modest antiviral effects, with challenges including drug resistance and toxicity.
- The need for more effective therapies targeting diverse stages of the HIV-1 life cycle was evident.
Purpose of the Study:
- To review available clinical data on newly approved HIV-1 protease inhibitors.
- To highlight advancements in HIV-1 treatment beyond nucleoside inhibitors.
Main Methods:
- Review of clinical data for approved HIV-1 protease inhibitors.
- Analysis of efficacy and limitations of previous HIV-1 treatment modalities.
Main Results:
- HIV-1 protease inhibitors represent a potent new class of antiviral compounds.
- These inhibitors significantly suppress HIV-1 replication, surpassing previous therapeutic achievements.
- Four protease inhibitors (saquinavir mesylate, ritonavir, nelfinavir, indinavir sulfate) are FDA-approved.
Conclusions:
- HIV-1 protease inhibitors offer a substantial improvement in managing HIV-1 infection.
- These agents provide greater viral suppression compared to earlier treatment options.
- Ongoing research continues to explore additional therapeutic agents.